Next on tap for Meridian Bioscience‘s (NASDAQ:VIVO) illumigene molecular diagnostic testing platform is a test for Mycoplasma pneumonia, an infection of the lungs. The illumigene Mycoplasma test is ...

Meridian Bioscience has filed an application for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system. Meridian’s ...

Scientists at Hackensack Meridian Health have developed a test that can detect multiple coronavirus variants within two-and-a-half hours, the Edison, N.J.-based system said April 1. The test is ...

illumigene® Malaria is more widely used than it was a year ago, but Meridian Bioscience says even more countries should use it." Researchers in Europe and philanthropists in New York are singing the ...

Diagnostic test kit maker Meridian Bioscience (VIVO) has won the approval of the U.S. Food and Drug Administration (:FDA) for its new test for detection of Legionnaire’s disease (legionellosis), a ...

Newtown-based Meridian Bioscience is deploying its newly developed test illumigene® Malaria in Dakar, Senegal and planning a rollout of this potentially life-saving diagnostic across Africa. A test ...

Hackensack Meridian Health announced Tuesday that a rapid test for COVID-19 created by its labs at the Center for Discovery and Innovation (CDI) has been licensed to T2 Biosystems, a ...

A new test developed by New Jersey's largest hospital network to detect COVID-19 variants may help public health officials understand how widespread the mutations are and how much they are ...